Ask AI
Immunotherapy for HCC
Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma

Released: July 22, 2025

Expiration: January 21, 2026

Activity

Progress
1
Course Completed

In this episode, Joseph W. Franses, MD, PhD; Neehar Parikh, MD, MS; and Mark Yarchoan, MD, share their thoughts on incorporating immune checkpoint inhibitors into the care of patients with HCC including:

  • Clinical Considerations for Selecting First-line Immunotherapy Combinations for Metastatic HCC
  • Overview of the Latest Data for the Combination of TACE With Immunotherapy (eg, EMERALD-1 Study of TACE and Durvalumab ± Bevacizumab for Unresectable HCC; and LEAP-012 Study of TACE + Lenvatinib + Pembrolizumab)
  • Latest Clinical Data and Updates for Systemic Therapy in Patients With High-Risk Early HCC